KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Shares Outstanding (Diluted Average) (2020 - 2025)

GoodRx Holdings' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $357.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 8.98% year-over-year to $357.0 million; the TTM value through Dec 2025 reached $357.0 million, down 8.98%, while the annual FY2025 figure was $357.0 million, 8.98% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $357.0 million at GoodRx Holdings, down from $361.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $416.4 million in Q3 2023 and bottomed at $357.0 million in Q4 2025.
  • The 5-year median for Shares Outstanding (Diluted Average) is $401.8 million (2021), against an average of $395.4 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) soared 49.25% in 2021 before it dropped 9.26% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $410.0 million in 2021, then increased by 0.7% to $412.9 million in 2022, then fell by 0.62% to $410.3 million in 2023, then dropped by 4.42% to $392.2 million in 2024, then dropped by 8.98% to $357.0 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Shares Outstanding (Diluted Average) are $357.0 million (Q4 2025), $361.4 million (Q3 2025), and $357.2 million (Q2 2025).